4.1 Million Raised by Fauna Bio (In Seed Funding) for Generation of Treatments for Human Illnesses

Fauna Bio (a biotechnology establishment leveraging the science of hibernation for better healthcare for humans), broadcasted that it has generated a total of $4.1 million in seed funding headed by True Ventures along with participation by Longevity Fund, Pacific 8 Ventures, Boom Capital and Beagle Ventures. The new funds will be used to expand the company’s discovery platform to assist in finding novel therapeutic targets for human ailments.

The drug-discovery platform’s first version looks at hibernating mammals, a principally striking chance for adaptation-inspired therapeutics. Hibernating animals have natural adaptations, presenting understandings into vital human health problems like Alzheimer’s disease, heart disease, obesity, traumatic injury, etc. These have moved initial treatments to improve survival following trauma, prolong storage for organs of transplant, and¬inhibit shivering while therapeutic hypothermia, but there is not an organized understanding of the gene networks used in generating the healing characteristics of hibernators.

“The current drug discovery process is broken,” stated Dr. Ashley Zehnder, CEO and the co-founder of Fauna Bio. “Historically, pharmaceutical companies have relied on a handful of species that often don’t recapitulate human diseases. Now, we are in a very exciting time where we have the ability to examine how species across the entire evolutionary tree combat diseases and live longer, healthier lives. At Fauna, we use these strategies and translate them into human therapies.”

Zehnder co-founded the Fauna Bio with Dr. Linda Goodman and Dr. Katharine Grabek. They met while working in the Bustamante Lab at Stanford University. Currently, the group has accomplished the whole genome, RNA, protein and metabolomic plus epigenetic sequencing from its internal biobank.

“Ashley, Linda and Katie are a great team with the diverse and complementary backgrounds required to lead deep innovation and succeed in his space,” stated Rohit Sharma. He is a partner at True Ventures. “Their expertise ties data and insights together in a way that will enable them to advance the best of hibernation science toward the development of new therapeutics.”